Champions Oncology, Inc. (NASDAQ:CSBR): A Comprehensive Analysis of Its Financial Performance

• Champions Oncology, Inc. (NASDAQ:CSBR) reported an earnings per share (EPS) of -$0.07, missing the estimated EPS of $0.06, with actual revenue of $12.36 million for the quarter.
• The company achieved a record annual revenue of $57 million for the fiscal year ending April 30, 2025, marking a 14% increase from the previous year.
• Despite a challenging quarter, CSBR reported a net income of $4.6 million and an adjusted EBITDA income of $7.1 million for the fiscal year, showcasing its resilience and potential for growth.

Champions Oncology, Inc. (NASDAQ:CSBR) is a key player in the field of translational oncology research. The company offers a range of preclinical and clinical research services to biopharmaceutical organizations. With a focus on oncology, CSBR leverages its extensive resources to provide comprehensive research and development solutions.

On July 23, 2025, CSBR reported its earnings, revealing an earnings per share (EPS) of -$0.07, which was below the estimated EPS of $0.06. The company's actual revenue for the period was $12.36 million, falling short of the estimated $14.67 million. Despite these figures, CSBR achieved a record annual revenue of $57 million for the fiscal year ending April 30, 2025, marking a 14% increase from the previous year.

The company also reported a net income of $4.6 million and an adjusted EBITDA income of $7.1 million for the fiscal year. Data license revenue contributed $4.7 million to the annual figures, showcasing the company's efforts to diversify its revenue streams. However, in the fourth quarter, CSBR experienced an adjusted EBITDA loss of $1.2 million, indicating some challenges in maintaining profitability.

CSBR's financial metrics provide further insight into its performance. The price-to-sales ratio stands at 1.83, suggesting how much investors are willing to pay per dollar of sales. The enterprise value to sales ratio is 1.88, reflecting the company's total valuation relative to its sales. However, the enterprise value to operating cash flow ratio is notably negative at -85.05, indicating challenges in generating cash flow relative to its enterprise value.

The company's debt-to-equity ratio is approximately 1.18, highlighting its use of debt financing relative to equity. The current ratio is around 0.99, suggesting CSBR's ability to cover its short-term liabilities with its short-term assets. Despite these challenges, CEO Ronnie Morris emphasized the significance of the past year, noting the company's return to growth and profitability, the launch of a high-margin data business, and the foundation laid for long-term value creation.